You are here: Industry Insights > msd

News List

AZ and MSD’s Lynparza shows significant results in ovarian cancer pharmatimes
October 25, 2018
AstraZeneca and MSD’s Lynparza improved progression-free survival by 70% compared to placebo in BRCA-mutated ovarian cancer patients who were in complete or partial response...
Strong results for Keytruda in head and neck cancer pharmatimes
October 25, 2018
MSD’s Keytruda improved overall survival by up to 39% in first-line head and neck cancer, new results show.
AZ/MSD’s Lynparza assigned Orphan status in US pharmatimes
October 19, 2018
AstraZeneca and MSD’s PARP inhibitor Lynparza has been granted orphan drug designation in the US for the treatment of pancreatic cancer.
Daiichi to test cancer drug combo pharmatimes
September 27, 2018
Daiichi Sankyo has entered into a clinical trial collaboration agreement with a subsidiary of MSD to evaluate a potential new combination...
US approves MSD HIV drugs Delstrigo and Pifeltro pharmatimes
September 14, 2018
MSD’s HIV medicines Delstrigo and Pifeltro have been cleared by the US Food and Drug Administration for adult patients with no prior antiretroviral treatment experience.
Priority review for MSD’s Keytruda for Merkel cell carcinoma pharmatimes
September 14, 2018
US regulators are undertaking a priority review of MSD’s Keytruda for the treatment of adult and paediatric patients with recurrent locally advanced...
MSD to file antibiotic Zerbaxa for pneumonia pharmatimes
September 13, 2018
MSD is gearing up to file antibiotic Zerbaxa on both sides of the Atlantic for certain forms of pneumonia on the success of a late-stage trial backing its safety and efficacy.
MSD's experimental vaccine to be used in fight against Congo Ebola outbreak pharmafile
August 09, 2018
MSD’s experimental drug rVSV-ZEBOV will be used in tackling the latest Ebola outbreak in the Democratic Republic of Congo, after samples collected from hospitalised patients tested positive for the filovirus.
MSD’s Keytruda Approved for Marketing in China in 164 Days, China to Speed Up to Enter the New Era of Immunotherapy 1°C
August 08, 2018
The State Drug Administration of China (SDA) updated the marketing application status of MSD’s Keytruda (pembrolizumab) on July 25, 2018 to “Approval completed-to be issued certificate”.
AZ and MSD get orphan designation for neurofibromatosis drug pharmatimes
August 06, 2018
The EMA has granted orphan designation to AstraZeneca and MSD's selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page